Early Detection of Prostate Cancer

Silent changes: why prostate cancer often becomes noticeable only at a later stage

In its early stages, prostate cancer generally causes no symptoms. Changes often affect only small areas of the prostate and initially have little influence on organ function. Symptoms therefore remain absent.

Without noticeable signs, many men have no reason to seek further assessment. Early diagnosis therefore requires examination methods that can detect changes before symptoms develop.

One blood value, many questions: what the PSA value can and cannot tell you

The PSA value describes the concentration of prostate-specific antigen in the blood. This protein is produced exclusively by cells of the prostate and enters the bloodstream in small amounts. When the prostate tissue changes, the PSA value often rises as well. For this reason, the test has been used for many years as a possible indicator of prostate cancer.

This is also where the limitations of the test become apparent. Benign enlargement or inflammatory processes can also increase the PSA value. Conversely, it can remain unremarkable in some men for a long time even though abnormal areas have already developed.

The PSA test is therefore an important warning signal, but it does not provide a definitive assessment.

Abnormal PSA value: what happens next?

A PSA value outside the normal range initially indicates only a deviation from the expected reference value.

A repeat blood test is therefore often performed after a defined interval to determine whether the PSA value continues to rise, remains stable or falls again.

A physical examination may also provide indications of larger areas of hardening. However, neither step shows where within the prostate a change is located or how extensive it is.

Early detection of prostate cancer with MRI: from suspicion to a visible assessment

Magnetic resonance imaging at our radiological prevention center in Düsseldorf enables direct visualization of the prostate and replaces assumptions with concrete image information.

MRI shows the prostate tissue in high resolution and makes differences visible that can remain hidden with other methods. Suspicious areas can be localized, assessed in terms of their extent and medically classified. This creates a considerably more precise picture of the individual situation.

For early detection, this is an important advantage: MRI helps identify relevant changes in good time and supports well-founded planning of the next steps. An early diagnosis generally offers good prospects for successful and less burdensome treatment.

Precise diagnostics with less burden: avoiding biopsy and gaining clarity

A prostate MRI can in many cases help avoid an immediate biopsy. If the examination shows unremarkable findings, this argues against the presence of clinically relevant tumors. A structured monitoring approach can then often be chosen instead of tissue sampling.

If further assessment is required, MRI supports planning. Suspicious areas can be localized precisely and, if necessary, examined in a targeted way. This reduces the number of unnecessary samples while significantly improving diagnostic accuracy.

Early detection of prostate cancer: who may benefit from prostate MRI and how often is it useful?

Prostate MRI is particularly suitable for men in whom conventional screening examinations do not provide a clear assessment. This includes abnormal or fluctuating PSA values, an increased family-related cancer risk and unclear previous findings that require further evaluation.

The examination intervals depend on the individual risk and the MRI result. If the findings are unremarkable, a follow-up after two to three years is often sufficient. If borderline abnormalities or an increased risk are present, a repeat examination after 12 months is generally recommended. In individual cases, intervals of 6 to 12 months may also be useful.

MRI offers particular advantages for follow-up. It does not use X-rays and does not expose the body to radiation even when examinations are repeated. This makes it well suited for long-term, safe early detection of prostate cancer.